drugset
drugset / Trial / NCT06903286

Extension Study of Participants From SPG302-ALS-001

NCT06903286 ↗

Phase 2 Terminated 16 enrolled Spinogenix
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)

Timeline

Start
2025-05-29
Primary completion
2025-06-30
Completion
2025-08-31

Outcome

Outcome not reported

Stopped: “patients treated through compassionate use program”

Drugs

EvaluationDrugModalityDoseRoute
Subject SPG302 Small molecule — Oral

Indications

amyotrophic lateral sclerosis